利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

137 条记录 (耗时 0.025 秒)

    LUNG CANCER BIOMARKERS AND USES THEREOF
    15.
    发明公开
    LUNG CANCER BIOMARKERS AND USES THEREOF 有权
    肺癌生物标志物及其用途

    公开(公告)号：EP2771692A2

    公开(公告)日：2014-09-03

    申请号：EP11874668.4

    申请日：2011-10-24

    申请人： Somalogic, Inc.

    发明人： RIEL-MEHAN, Michael ,  STEWART, Alex, A.E. ,  OSTROFF, Rachel, M. ,  WILLIAMS, Stephen, Alaric ,  BRODY, Edward, N.

    IPC分类号： G01N33/574

    CPC分类号： G01N33/57423 ,  G01N2800/60

    摘要： The present application includes biomarkers, methods, devices, reagents, systems, and kits for the detection and diagnosis of non-small cell lung cancer and general cancer. In one aspect, the application provides biomarkers that can be used alone or in various combinations to diagnose non-small cell lung cancer or general cancer. In another aspect, methods are provided for diagnosing non-small cell lung cancer in an individual, where the methods include detecting, in a biological sample from an individual, at least one biomarker value corresponding to at least one biomarker selected from the group of biomarkers provided in Table 1, wherein the individual is classified as having lung cancer, or the likelihood of the individual having lung cancer is determined, based on the at least one biomarker value. In another aspect, methods are provided for diagnosing cancer in an individual, where the methods include detecting, in a biological sample from an individual, at least one biomarker value corresponding to at least one biomarker selected from the group of biomarkers provided in Table 19, wherein the individual is classified as having cancer, or the likelihood of the individual having cancer is determined, based on the at least one biomarker value.

    摘要翻译： 本申请包括用于检测和诊断非小细胞肺癌和一般癌症的生物标志物，方法，装置，试剂，系统和试剂盒。 在一个方面，本申请提供了可以单独或以各种组合使用来诊断非小细胞肺癌或一般癌症的生物标记。 另一方面，提供了用于诊断个体中的非小细胞肺癌的方法，其中所述方法包括在来自个体的生物样品中检测对应于选自生物标志物组的至少一种生物标志物的至少一个生物标志物值 提供于表1中，其中基于所述至少一种生物标志物值，所述个体被分类为患有肺癌，或所述个体患有肺癌的可能性。 另一方面，提供了用于诊断个体中的癌症的方法，其中所述方法包括在来自个体的生物样品中检测对应于选自表19中提供的生物标志物组的至少一种生物标志物的至少一种生物标志物值， 其中所述个体被分类为患有癌症，或基于所述至少一个生物标志物值确定所述个体患有癌症的可能性。

    Chemically modified aptamers with improved off-rates
    16.
    发明公开
    Chemically modified aptamers with improved off-rates 有权
    Aptamere mit 5-（N-Naphthyl）-ubstituiertem Uridin

    公开(公告)号：EP2489743A2

    公开(公告)日：2012-08-22

    申请号：EP12160299.9

    申请日：2008-07-17

    申请人： Somalogic, Inc.

    发明人： Zichi, Dominic ,  Wilcox, Sheri K. ,  Bock, Chris ,  Schneider, Daniel J. ,  Eaton, Bruce ,  Gold, Larry

    IPC分类号： C12Q1/68

    CPC分类号： C12Q1/6811 ,  C12N15/1048 ,  C12N15/111 ,  C12N15/115 ,  C12N2310/16 ,  C12N2320/13 ,  C12Q2541/101 ,  C12Q2525/205 ,  C12Q2525/117

    摘要： The present disclosure describes improved SELEX methods for producing aptamers that are capable of binding to target molecules and improved photoSELEX methods for producing photo reactive aptamers that are capable of both binding and covalently cross linking to target molecules. Specifically, the present disclosure describes methods for producing aptamers and photoaptamers having slower dissociation rate constants than are obtained using prior SELEX and photoSELEX methods. The disclosure further describes aptamers and photoaptamers having slower dissociation rate constants than those obtained using prior methods. In addition, the disclosure describes aptamer constructs that include a variety of functionalities, including a cleavable element, a detection element, and a capture or immobilization element.

    摘要翻译： 本公开描述了用于产生能够结合靶分子的适配体的改进的SELEX方法，以及用于产生能够结合和共价交联到靶分子的光反应性适体的改进的光学光学法。 具体地，本公开描述了用于生产具有比使用先前的SELEX和photoSELEX方法获得的解离速率常数更慢的适体和光致抗体的方法。 本公开进一步描述了具有比使用现有方法获得的那些更快的解离速率常数的适体和光致抗体。 此外，本公开描述了包括多种功能的适体构建体，包括可切割元件，检测元件和捕获或固定元件。

    METHOD FOR GENERATING APTAMERS WITH IMPROVED OFF-RATES
    17.
    发明公开
    METHOD FOR GENERATING APTAMERS WITH IMPROVED OFF-RATES 有权
    工艺制造还原故障率适体

    公开(公告)号：EP2451981A1

    公开(公告)日：2012-05-16

    申请号：EP10797920.5

    申请日：2010-07-09

    申请人： Somalogic, Inc.

    发明人： ZICHI, Dominic ,  WILCOX, Sheri K. ,  BOCK, Chris ,  SCHNEIDER, Daniel J. ,  EATON, Bruce ,  GOLD, Larry ,  JARVIS, Thale C. ,  CARTER, Jeffrey D.

    IPC分类号： C12Q1/68

    CPC分类号： C12N15/1048 ,  C12Q1/6811 ,  C12Q2525/205

    摘要： The present disclosure describes methods for producing aptamers and photoaptamers having slower dissociation rate constants than are obtained using prior SELEX and photoSELEX methods. The disclosure further describes aptamers and photoaptamers having slower dissociation rate constants than those obtained using prior methods. This invention relates to the field of diagnostic histology, cytology, histopathology, and cytopathology methods and reagents for the detection of various disease states. More specifically, the invention relates to the use of aptamers in histologic, cytologic, histopathic, and/or cytopathic diagnostic methods. Aptamers may be provided that react with specific target molecules contained within a histological or cytological sample. Aptamers may be used to assess localization, relative density, and presence or absence of one or more target. Targets may be selected that are specific and diagnostic of a given disease state for which the sample was collected. Aptamers may be used to introduce target specific signal moieties. Antigen retrieval methods may be applied to the sample prior to reaction with the specific aptamer/s to improve interaction of the aptamer and target within the sample. Or aptamers may be developed for the specific target that eliminates the need for the antigen retrieval process. In addition to target identification, aptamers may be used to amplify signal generation through a variety of methods.

    OVARIAN CANCER BIOMARKERS AND USES THEREOF
    18.
    发明公开
    OVARIAN CANCER BIOMARKERS AND USES THEREOF 审中-公开
    卵巢癌生物标志物及其用途

    公开(公告)号：EP2350917A1

    公开(公告)日：2011-08-03

    申请号：EP09819761.9

    申请日：2009-10-06

    申请人： Somalogic, Inc.

    发明人： GOLD, Larry ,  STANTON, Marty ,  BRODY, Edward N. ,  OSTROFF, Rachel M. ,  ZICHI, Dominic ,  STEWART, Alex A.E.

    IPC分类号： G06G7/58 ,  G01N33/50

    CPC分类号： G01N33/57449 ,  G06F19/24

    摘要： The present application includes biomarkers, methods, devices, reagents, systems, and kits for the detection and diagnosis of ovarian cancer. In one aspect, the application provides biomarkers that can be used alone or in various combinations to diagnose ovarian cancer or permit the differential diagnosis of a pelvic mass as benign or malignant. In another aspect, methods are provided for diagnosing ovarian cancer in an individual, where the methods include detecting, in a biological sample from an individual, at least one biomarker value corresponding to at least one biomarker selected from the group of biomarkers provided in Table 1, wherein the individual is classified as having ovarian cancer, or the likelihood of the individual having ovarian cancer is determined, based on the at least one biomarker value.

    LUNG CANCER BIOMARKERS AND USES THEREOF
    19.
    发明公开
    LUNG CANCER BIOMARKERS AND USES THEREOF 有权
    生物标志物对肺癌和使用

    公开(公告)号：EP2340506A1

    公开(公告)日：2011-07-06

    申请号：EP09813557.7

    申请日：2009-09-09

    申请人： Somalogic, Inc.

    发明人： GOLD, Larry ,  STANTON, Marty ,  BRODY, Edward, N. ,  OSTROFF, Rachel, M. ,  ZICHI, Dominic ,  STEWART, Alex A., E.

    IPC分类号： G06G7/58 ,  G01N33/50

    CPC分类号： G01N33/57423 ,  G06F19/00 ,  Y02A90/26

    摘要： The present application includes biomarkers, methods, devices, reagents, systems, and kits for the detection and diagnosis of lung cancer. In one aspect, the application provides biomarkers that can be used alone or in various combinations to diagnose lung cancer or permit the differential diagnosis of pulmonary nodules as benign or malignant. In another aspect, methods are provided for diagnosing lung cancer in an individual, where the methods include detecting, in a biological sample from an individual, at least one biomarker value corresponding to at least one biomarker selected from the group of biomarkers provided in Table 1, Co1. 2, wherein the individual is classified as having lung cancer, or the likelihood of the individual having lung cancer is determined, based on the at least one biomarker value.